Literature DB >> 16176259

Antiplasmin: the forgotten serpin?

Paul B Coughlin1.   

Abstract

Much of the basic biochemistry of antiplasmin was described more than 20 years ago and yet it remains an enigmatic member of the serine protease inhibitor (serpin) family. It possesses all of the characteristics of other inhibitory serpins but in addition it has unique N- and C-terminal extensions which significantly modify its activities. The N-terminus serves as a substrate for Factor XIIIa leading to crosslinking and incorporation of antiplasmin into a clot as it is formed. Although free antiplasmin is an excellent inhibitor of plasmin, the fibrin bound form of the serpin appears to be the major regulator of clot lysis. The C-terminal portion of antiplasmin is highly conserved between species and contains several charged amino acids including four lysines with one of these at the C-terminus. This portion of the molecule mediates the initial interaction with plasmin and is a key component of antiplasmin's rapid and efficient inhibitory mechanism. Studies of mice with targeted deletion of antiplasmin have confirmed its importance as a major regulator of fibrinolysis and re-emphasized its value as a potential therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16176259     DOI: 10.1111/j.1742-4658.2005.04881.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  18 in total

1.  Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating α2-antiplasmin.

Authors:  Guy L Reed; Aiilyan K Houng; Dong Wang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-09-25       Impact factor: 8.311

2.  Plasminogen-receptor KT : plasminogen activation and beyond.

Authors:  M J Flick; T H Bugge
Journal:  J Thromb Haemost       Date:  2016-11-25       Impact factor: 5.824

3.  Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites.

Authors:  Galina Tsurupa; Sergiy Yakovlev; Patrick McKee; Leonid Medved
Journal:  Biochemistry       Date:  2010-09-07       Impact factor: 3.162

4.  X-ray crystal structure of plasmin with tranexamic acid-derived active site inhibitors.

Authors:  Ruby H P Law; Guojie Wu; Eleanor W W Leung; Koushi Hidaka; Adam J Quek; Tom T Caradoc-Davies; Devadharshini Jeevarajah; Paul J Conroy; Nigel M Kirby; Raymond S Norton; Yuko Tsuda; James C Whisstock
Journal:  Blood Adv       Date:  2017-05-09

Review 5.  The plasmin-antiplasmin system: structural and functional aspects.

Authors:  Johann Schaller; Simon S Gerber
Journal:  Cell Mol Life Sci       Date:  2010-12-07       Impact factor: 9.261

6.  Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin.

Authors:  K N Lee; K W Jackson; V J Christiansen; E K Dolence; P A McKee
Journal:  J Thromb Haemost       Date:  2011-05       Impact factor: 5.824

7.  Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities.

Authors:  David F Moore; Oleg V Krokhin; Ronald C Beavis; Markus Ries; Chevalia Robinson; Ehud Goldin; Roscoe O Brady; John A Wilkins; Raphael Schiffmann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-14       Impact factor: 11.205

8.  Contribution of conserved lysine residues in the alpha2-antiplasmin C terminus to plasmin binding and inhibition.

Authors:  Bernadine G C Lu; Trifina Sofian; Ruby H P Law; Paul B Coughlin; Anita J Horvath
Journal:  J Biol Chem       Date:  2011-05-04       Impact factor: 5.157

9.  Genomic abnormalities of the murine model of Fabry disease after disease-related perturbation, a systems biology approach.

Authors:  David F Moore; Monique P Gelderman; Paulo A Ferreira; Steven R Fuhrmann; Haiqing Yi; Abdel Elkahloun; Lisa M Lix; Roscoe O Brady; Raphael Schiffmann; Ehud Goldin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

Review 10.  Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?

Authors:  Be'eri Niego; Robert L Medcalf
Journal:  J Cereb Blood Flow Metab       Date:  2014-06-04       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.